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Background
Pro-inflammatory changes as well as dyslipidaemia are
believed to be causally implicated in the increased risk of
cardiovascular events in patients with HIV infection
treated with combination antiretroviral therapy. Treat-
ment with n-3 polyunsaturated fatty acids (fish oil) is
known to reduce plasma triglycerides in subjects without
HIV infection, and preliminary studies have observed a
moderate reduction in triglycerides in HIV infection fol-
lowing 8–12 weeks of supplementation with fish oil.
However, the impact of n-3 fatty acids on inflammatory
mediators has not previously been studied in this popula-
tion.
Methods
We examined 48 patients treated with combination
antiretroviral therapy. Patients were randomised to treat-
ment with Omacor 4 g per day (2 g BID) equal to 3.6 g of
omega-3 fatty acids or control for 12 weeks. Compliance
was monitored by measuring the incorporation of eicos-
apentaenoic acid (EPA) and docosahexaenoic acid (DHA)
into blood neutrophils. The aim of the study was to inves-
tigate the effect of Omacor on formation of leukotriene B4
(LTB4) with very potent pro-inflammatory effects and leu-
kotriene B5 (LTB5) from stimulated blood neutrophils at
baseline and after 12 weeks of supplement. In addition,
we measured highly sensitive C-reactive protein, vascular
cell adhesion molecule-1 and soluble intercellular adhe-
sion molecule-1.
Summary of Results
Following 12 weeks of treatment, EPA and DHA increased
significantly in blood neutrophils in the Omacor group (n
= 25), from 0.5% to 1.8% for EPA and from 1.4% to 2.0%
for DHA, p < 0.0001, whereas no change was observed in
the control group (n = 23). Formation of LTB4 decreased
in the Omacor group (150 ng to 133 ng, p = 0.0005),
whereas LTB5 increased from 4 ng to 12 ng, p < 0.0001.
Thus, the inflammatory balance mediated by the leukot-
riene system, changed in a beneficial anti-inflammatory
direction following Omacor supplementation, whereas
no change was observed in the control group. We found
no effect of Omacor treatment on the other inflammatory
markers.
Conclusion
In conclusion, treatment with Omacor significantly
reduced the inflammatory activity of the leukotriene sys-
tem in HIV patients receiving combination antiretroviral
therapy which potentially might reduce their risk of
atherosclerosis and cardiovascular events.
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